Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Shorts Increased By 7.12%

April 17, 2018 - By Michele Cranor

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Corporate Logo

It was noted an increase on Adamas Pharmaceuticals Inc (NASDAQ:ADMS)’s shorted shares with 7.12%. It was issued in April by FINRA the 7.68M shorted shares on ADMS. That’s 7.12% up from 7.17 million shares. Previous ADMS’s position will need 8 days to recover. It has 943,400 average volume. 65.18% is Adamas Pharmaceuticals Inc float short.

On during the last trading session the stock increased $0.26 or 1.08%, reaching $24.37.Currently Adamas Pharmaceuticals, Inc. is uptrending after 35.83% change in last April 17, 2017. ADMS has 201,378 shares volume. The stock outperformed the S&P 500 by 24.28%.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders.The firm is worth $653.29 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease.Last it reported negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Total analysts of 8 have positions in Adamas Pharmaceuticals (NASDAQ:ADMS) as follows: 8 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $85 highest while $3100 is the lowest [Target]. The average target $51.38 is 110.83% above the last ($24.37) price. Since October 30, 2017 according to StockzIntelligence Inc Adamas Pharmaceuticals has 13 analyst reports. On Tuesday, February 20 Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating. Mizuho has “Buy” rating and $48.0 target. On Tuesday, January 30 the firm earned “Buy” rating by Piper Jaffray. On Wednesday, November 8 Noble Financial maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) with “Buy” rating. On Wednesday, April 4 Leerink Swann initiated Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating. Leerink Swann has “Buy” rating and $3100 target. On Wednesday, November 29 the rating was initiated by Northland Capital with “Buy”. On Tuesday, February 20 the stock has “Buy” rating by Evercore. On Friday, February 23 the rating was maintained by Needham with “Buy”. On Friday, November 3 the firm has “Buy” rating given by Mizuho. On Friday, March 9 the rating was maintained by Mizuho with “Buy”. On Tuesday, January 23 the stock has “Buy” rating by Mizuho.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: